Group 1 - The core point of the announcement is that the company, Yabao Pharmaceutical Group Co., Ltd., is transferring part of its equity in Wuhan Jianmin Capital Partnership to its wholly-owned subsidiary, Yabao Ailegao, and is also withdrawing from the partnership to optimize external investments and improve asset operation efficiency [1][7]. Group 2 - The company signed an equity transfer agreement with Zhejiang Huafang Asset Management Co., Ltd., acquiring a 40.68% stake in Wuhan Jianmin Capital with a subscribed capital of 120 million RMB, while the actual paid-in capital was 0 RMB [1]. - After a capital reduction, the total capital contribution of all partners in Jianmin Capital was 274.58 million RMB, with the company holding a 43.70% stake [2]. - The company transferred 5 million shares of Jianmin Capital for 49.0235 million RMB to Yabao Ailegao and withdrew from 7 million shares for 68.633 million RMB [2][5]. Group 3 - The total capital contribution of Jianmin Capital after the transfer and withdrawal will be reduced to 204.58 million RMB, with Yabao Ailegao holding a 24.44% stake [6]. - The net asset value of Jianmin Capital as of December 31, 2024, was reported at 253.7888 million RMB [5]. Group 4 - The purpose of this transaction is to optimize external investments and recover funds, which will enhance the company's asset operation efficiency without adversely affecting its normal production and financial status [7].